URGN FY 2024 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M+9.3% YoY

Gross Profit

$82M90.2% margin

Operating Income

-$97M-107.1% margin

Net Income

-$127M-140.4% margin

EPS (Diluted)

$-2.96

Cash Flow

Operating Cash Flow

-$97M

Free Cash Flow

-$97M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$286M

Total Liabilities

$295M

Stockholders' Equity

-$9M

Cash & Equivalents

$172M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$83M	+9.3%
Gross Profit	$82M	$73M	+11.1%
Operating Income	-$97M	-$66M	-47.7%
Net Income	-$127M	-$102M	-24.1%